Skip Navigation


European Heart Journal Advance Access originally published online on March 8, 2007
European Heart Journal 2007 28(6):659-660; doi:10.1093/eurheartj/ehl574
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
28/6/659    most recent
ehl574v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Agostoni, P.
Right arrow Articles by Banfi, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Agostoni, P.
Right arrow Articles by Banfi, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Matrix metalloproteinase and heart failure: is it time to move from research to clinical laboratories?

Piergiuseppe Agostoni1,2,4,* and Cristina Banfi1,3

1 Centro Cardiologico Monzino, IRCCS, Via Parea 4, 20138 Milan, Italy
2 Istituto di Cardiologia, Università degli Studi di Milano, Milan, Italy
3 Dipartimento di Scienze Farmacologiche, Università degli Studi di Milano, Milan, Italy
4 Division of Respiratory and Critical Care Medicine, University of Washington, Seattle, WA 98185, USA

* Corresponding author. Tel: +39 02 58002299; fax: +39 02 58002383. E-mail address: piergiuseppe.agostoni@ccfm.it

This editorial refers to ‘Plasma matrix metalloproteinase-9 and left ventriclar remodelling after acute myocardial infarction in man: a prospective cohort study’{dagger} by D. Kelly et al., on page 711

The first 10% of the full text of this article appears below.

In basic science research laboratories dedicated to heart failure, several substances have been studied as candidate markers of the disease's severity, as target of therapy and as indicators of therapheutical success. Many potential biological markers have emerged and are now under research, among which, markers of myocyte injury (e.g. troponins), markers of inflammation (e.g. tumour necrosis factor {alpha}, IL-6), markers of oxidative stress (e.g. urinary byopyrrins), markers of sodium pump activity (e.g. caridiotonics steroids), and a separate group of peptides associated with heart failure.1 However, at present, only natriuretic peptides, in particular, B-type natriuretic peptide, has an established clinical impact. Several reasons account for the frequent failure for substances under research to reach clinical laboratories . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study
Dominic Kelly, Gillian Cockerill, Leong L. Ng, Matt Thompson, Sohail Khan, Nilesh J. Samani, and Iain B. Squire
EHJ 2007 28: 711-718. [Abstract] [FREE Full Text]